[Federal Register Volume 68, Number 11 (Thursday, January 16, 2003)]
[Notices]
[Page 2346]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-936]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director


Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should inform the contact person below in advance of 
the meeting.

    Name of Committee: Recombinant DNA Advisory Committee (RAC).
    Date: January 17, 2003.
    Time: 9:30 a.m. to 3 p.m.
    Agenda: The Committee will review new data from a retroviral-
mediated gene transfer clinical trial in Severe Combined 
Immunodeficiency (SCID) that could be important to the safety of 
participants in gene transfer clinical trials that use retroviral 
vectors. The discussion of this new information may lead to changes 
in the recommendations on the safety of the clinical gene transfer 
trials in SCID formulated by the RAC at its December 2002 meeting. 
In addition, the RAC may make recommendations pertaining to the 
safety and conduct of gene transfer clinical trials using retroviral 
vectors.
    The RAC is meeting due to the potential significance of this new 
data and the need for expeditious deliberation and public discussion 
of its potential implications for the safety and conduct of clinical 
gene transfer trials using retroviral vectors.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 45, Conference Room F1/F2, Bethesda, Maryland 20892.
    Contact: Stephen Rose, Ph.D., Executive Secretary, Recombinant 
DNA Advisory Committee, Office of Biotechnology Activities, 
Rockledge 1, Room 750, Bethesda, MD 20892. (301) 496-9839.
    Information is also available on the Institute's/Center's home 
page: http://www4.od.nih.gov/oba/, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecules techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual programs listed in the Catalog of Federal 
Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.187, Undergraduate 
Scholarship Program for Individuals from Disadvantaged Backgrounds; 
93.22, Clinical Research Loan Repayment Program for Individuals from 
Disadvantaged Backgrounds; 93.232, Loan Repayment Program for 
Research Generally; 93.39, Academic Research Enhancement Award; 
93.936, NIH Acquired Immunodeficiency Syndrome Research Loan 
Repayment Program, National Institutes of Health, HHS)
    Dated: January 10, 2003.
Anna P. Snouffer,
Director, Office of Federal Advisory Committee Policy.
    This notice is being published less than 15 days before the 
meeting due to the emergency nature of the actions involved.
[FR Doc. 03-936 Filed 1-15-03; 8:45 am]
BILLING CODE 4140-01-M